Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RANKL monoclonal antibody to promote healing after rotator cuff repair in elderly women
ChiCTR2200065579Phase 4Recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Dec 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4 trial of denosumab in rotator cuff tear and osteoporosis (2 arms), sponsored by West China Hospital of Sichuan University. Primary endpoints: Bone mineral density (BMD), MRI of shoulder and 3 more. Started Dec 2022; status: recruiting.
02
Drugs
denosumab
03
Conditions
rotator cuff tearosteoporosis
Beyond the preview
Go deeper on ChiCTR2200065579.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200065579.